Assessment of patients with psoriatic arthritis: a review of currently available measures.
about
Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnClinical outcomes in psoriatic arthritis: A systematic literature reviewSurvival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors.Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.High-resolution uniform MR imaging of finger joints using a dedicated RF coil at 3TEnumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis.Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept.Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritisUpdated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Consensus exercise on domains in psoriatic arthritis.Psoriatic arthritis assessment tools in clinical trials.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Psoriasis: emerging therapeutic strategies.Guideline for anti-TNF-alpha therapy in psoriatic arthritis.Preliminary identification of core domains for outcome studies in psoriatic arthritis using Delphi methodsOMERACT 7 psoriatic arthritis workshop: synopsis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgarisThe Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version.Psoriasis and psoriatic arthritis: separate or one and the same?The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.Treatment recommendations for psoriatic arthritis.Inflammatory arthritis: an overview for primary care physicians.Ustekinumab for the treatment of psoriasis.Biomarkers in psoriatic arthritis: a systematic literature review.Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study.Vitamin D3 levels and bone mineral density in patients with psoriasis and/or psoriatic arthritis.Clinical and radiological damage in psoriatic arthritis.Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo.The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.Physician scores vs patient self-report of joint and skin manifestations in psoriatic arthritis.Psoriatic arthritis mutilans (PAM) in the Nordic countries: demographics and disease status. The Nordic PAM study.Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and radiography follow-up study during adalimumab therapy.Differences in bone structure between rheumatoid arthritis and psoriatic arthritis patients relative to autoantibody positivity.
P2860
Q26862017-6AB25D88-8EF0-4366-AD29-0C1857B9C2D0Q26995307-97E6DC8A-B1F8-4C15-AF3F-70E479DE3D09Q31036925-322452F2-96D8-4356-A85E-34363F20BF13Q31038425-C0B6B75F-ADBE-4CFF-8D1A-03D1B7A91D6AQ33566374-316350D9-6FC2-4A42-A1F5-72FB40FB1D03Q34027624-99F4C5F6-669D-4D99-AAC9-1159A5DEC536Q34063843-E6CD902C-9D81-4656-9CAE-1FC37398B8BDQ34896320-51B4BDC1-E643-46ED-BD7C-79BA21273F9AQ35555675-8E31790B-EF1B-4416-A235-95B0C1079395Q35555882-1B5F5D20-E6B5-446D-B624-9ADF9521CEEDQ35579352-49EE7C41-A2FE-46A2-9485-D36DC4790F24Q35579421-869C651D-93DE-4F98-A551-8B586E1A52E4Q35579462-8056708B-F962-4BED-8435-D0627D3F8930Q35579517-5476FE8C-9706-4D25-99A8-87342612083AQ35636983-35E118E8-2672-4CF2-9CE7-B30C0E411099Q35638252-861574E1-7CBA-4A82-B25B-501AADABCEC5Q36028220-1180C5DE-C9B7-49FE-AD2F-9D415396C148Q36032569-5F493F73-EAE1-4B62-9489-8A89C829AB25Q36040023-10C0CE2E-DEFA-4E8D-B27A-0255C04A6E69Q36040030-47D6B8FB-E348-411C-9064-E45CDE326C3FQ36171750-8EAEE5C4-AB30-4C0F-BC76-CB38B7C40965Q36733774-DFBAD4EA-72DB-4D6B-9FAB-514AF2EDFD5CQ36833558-357E293B-098D-49A1-9B9A-D5AB596103AAQ36921661-974B0A21-31E3-40FB-9FEA-707A6EABEB4EQ36940942-E5E61249-9DD4-4CC2-8935-857E76B36D4AQ37284516-4B6FB9CB-05F9-4D88-8D4A-B53BD6E8E9E0Q37427257-593D2F28-096D-4A28-B30F-1A55540F7047Q37855945-E3BBB0A0-F8AD-4B4C-AD89-ACF29FC64306Q38715137-E124F187-35BA-4113-8ABA-9B315C281F3EQ39837952-17D896A0-5808-4F09-A7AB-BF01ECCA7873Q39872599-46F544B5-CA67-40A7-9F21-36A78B3C7A4CQ40955608-A8BFD0FD-5614-4391-8C4F-F17033029C63Q42174115-15233C2B-127E-4D7A-9629-6E5145BA656CQ42955115-5CC8C2E6-0159-4D24-AB4D-1D9327891DEBQ42955288-9C5E309A-FD28-4B17-B2D2-5C17F25692B7Q42955715-C54510D7-2FD6-4144-9C2D-DC90867328D2Q44220233-2EEBF501-4A0A-4E24-86CB-EB57A1CD7218Q45841874-43A782E3-59F4-4FF5-9229-EA16C3E7D1BBQ46876696-E4059388-267E-4839-A0DB-F2599E110064Q47831537-87C487E8-B9E9-4321-8938-DAB1CF610D47
P2860
Assessment of patients with psoriatic arthritis: a review of currently available measures.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Assessment of patients with ps ...... currently available measures.
@ast
Assessment of patients with ps ...... currently available measures.
@en
type
label
Assessment of patients with ps ...... currently available measures.
@ast
Assessment of patients with ps ...... currently available measures.
@en
prefLabel
Assessment of patients with ps ...... currently available measures.
@ast
Assessment of patients with ps ...... currently available measures.
@en
P2093
P356
P1476
Assessment of patients with ps ...... currently available measures.
@en
P2093
Christopher Ritchlin
Peter Nash
Philip J Mease
William Taylor
P356
10.1002/ART.11417
P577
2004-01-01T00:00:00Z